Zorvolex(dicofenac) for management of Osteoarthritis(joint disorder) from Iroko Pharma gets US FDA approval.Zorvolex(diclofenac) is developed with proprietary SoluMatrix FINE PARTICLE TECHNOLOGY in which diclofenac is in submicron particles form that are approximately 20 times smaller than original size.This reduction in particle size results in increased surface area which leads to faster dissolution , prompt effect.
According to Iroko Pharma, Zorvolex was developed keeping in line with recommendations from US FDA and others that NSAIDs be used in lowest effective dose for short possible duration with individual patient treatment goal.
According to Iroko Pharma, Zorvolex was developed keeping in line with recommendations from US FDA and others that NSAIDs be used in lowest effective dose for short possible duration with individual patient treatment goal.